{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T15:05:11Z","timestamp":1793804711619,"version":"4.6.1"},"reference-count":109,"publisher":"The Endocrine Society","issue":"11","funder":[{"DOI":"10.13039\/501100012264","name":"NIH","doi-asserted-by":"publisher","award":["ZIA-DA000635"],"award-info":[{"award-number":["ZIA-DA000635"]}],"id":[{"id":"10.13039\/501100012264","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100030692","name":"National Institute on Drug Abuse Intramural Research Program","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100030692","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000027","name":"National Institute on Alcohol Abuse","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000027","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Alcoholism Division of Intramural Clinical and Biological Research"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Alcohol and other substance use disorders (ASUDs) are complex, multifaceted, but treatable medical conditions with widespread medical, psychological, and societal consequences. However, treatment options remain limited, therefore the discovery and development of new treatments for ASUDs is critical. Glucagon-like peptide-1 receptor agonists (GLP-1RAs), currently approved for the treatment of type 2 diabetes mellitus, obesity, and obstructive sleep apnea, have recently emerged as potential new pharmacotherapies for ASUDs. Following an overview of the epidemiology, biology, consequences, and treatments of ASUDs, this review provides a summary of the emerging role of GLP-1RAs in the treatment of ASUDs by elucidating their interactions with various neurobiological pathways involved in addiction. We also highlight existing gaps in research, future directions, and broader implications related to the potential use of GLP-1RAs for addiction treatment.<\/jats:p>","DOI":"10.1210\/jendso\/bvaf141","type":"journal-article","created":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T11:40:54Z","timestamp":1756467654000},"source":"Crossref","is-referenced-by-count":26,"title":["GLP-1 Therapeutics and Their Emerging Role in Alcohol and Substance Use Disorders: An Endocrinology Primer"],"prefix":"10.1210","volume":"9","author":[{"given":"Nirupam M","family":"Srinivasan","sequence":"first","affiliation":[{"name":"School of Medicine, University of Galway , Galway H91 TK33 ,","place":["Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0902-4212","authenticated-orcid":false,"given":"Mehdi","family":"Farokhnia","sequence":"additional","affiliation":[{"name":"Clinical Psychoneuroendocrinology and Neuropsychopharmacology Section, Translational Addiction Medicine Branch, National Institute on Drug Abuse (NIDA) Intramural Research Program, National Institute on Alcohol Abuse and Alcoholism (NIAAA) Division of Intramural Clinical and Biological Research, NIH , Baltimore, MD 21224 ,","place":["USA"]},{"name":"Department of Mental Health, Johns Hopkins Bloomberg School of Public Health , Baltimore, MD 21205 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa A","family":"Farinelli","sequence":"additional","affiliation":[{"name":"Office of the Clinical Director, National Institute on Drug Abuse (NIDA) Intramural Research Program , Baltimore, MD 21224 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Ferrulli","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences for Health, University of Milan , Milan 20133 ,","place":["Italy"]},{"name":"Department of Endocrinology, Nutrition and Metabolic Diseases, IRCCS MultiMedica , Milan 20138 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7284-8754","authenticated-orcid":false,"given":"Lorenzo","family":"Leggio","sequence":"additional","affiliation":[{"name":"Clinical Psychoneuroendocrinology and Neuropsychopharmacology Section, Translational Addiction Medicine Branch, National Institute on Drug Abuse (NIDA) Intramural Research Program, National Institute on Alcohol Abuse and Alcoholism (NIAAA) Division of Intramural Clinical and Biological Research, NIH , Baltimore, MD 21224 ,","place":["USA"]},{"name":"Office of the Clinical Director, National Institute on Drug Abuse (NIDA) Intramural Research Program , Baltimore, MD 21224 ,","place":["USA"]},{"name":"Department of Endocrinology, Nutrition and Metabolic Diseases, IRCCS MultiMedica , Milan 20138 ,","place":["Italy"]},{"name":"Center for Alcohol and Addiction Studies, Department of Behavioral and Social Sciences, Brown University , Providence, RI 02903 ,","place":["USA"]},{"name":"Division of Addiction Medicine, Department of Medicine, School of Medicine, Johns Hopkins University , Baltimore, MD 21224 ,","place":["USA"]},{"name":"Department of Neuroscience, Georgetown University Medical Center , Washington, DC 20007 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2025,10,9]]},"reference":[{"key":"2025100909011254800_bvaf141-B1","volume-title":"Desk Reference to the Diagnostic Criteria from DSM-5","author":"American Psychiatric Association","year":"2013"},{"key":"2025100909011254800_bvaf141-B2","author":"World Health Organization"},{"issue":"6):","key":"2025100909011254800_bvaf141-B3","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S2215-0366(25)00060-4","article-title":"Reevaluating the brain disease model of addiction","volume":"12","author":"Blithikioti","year":"2025","journal-title":"Lancet Psychiatry"},{"issue":"10","key":"2025100909011254800_bvaf141-B4","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1038\/s41386-020-00950-y","article-title":"Addiction as a brain disease revised: why it still matters, and the need for consilience","volume":"46","author":"Heilig","year":"2021","journal-title":"Neuropsychopharmacology"},{"issue":"8","key":"2025100909011254800_bvaf141-B5","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S2215-0366(16)00104-8","article-title":"Neurobiology of addiction: a neurocircuitry analysis","volume":"3","author":"Koob","year":"2016","journal-title":"Lancet Psychiatry"},{"issue":"1","key":"2025100909011254800_bvaf141-B6","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1146\/annurev-pharmtox-031323-115847","article-title":"Alcohol use disorder treatment: problems and solutions","volume":"64","author":"Koob","year":"2024","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"2025100909011254800_bvaf141-B7","author":"Substance Abuse and Mental Health Services Administration"},{"key":"2025100909011254800_bvaf141-B8","author":"World Health Organization"},{"issue":"9752","key":"2025100909011254800_bvaf141-B9","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/S0140-6736(10)61462-6","article-title":"Drug harms in the UK: a multicriteria decision analysis","volume":"376","author":"Nutt","year":"2010","journal-title":"The Lancet"},{"issue":"10","key":"2025100909011254800_bvaf141-B10","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1007\/s11606-021-07069-w","article-title":"National prevalence of alcohol and other substance use disorders among emergency department visits and hospitalizations: NHAMCS 2014\u20132018","volume":"37","author":"Suen","year":"2022","journal-title":"J Gen Intern Med"},{"issue":"8","key":"2025100909011254800_bvaf141-B11","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1001\/jamapsychiatry.2021.1271","article-title":"Use of medications for alcohol use disorder in the US","volume":"78","author":"Han","year":"2021","journal-title":"JAMA Psychiatry"},{"issue":"2","key":"2025100909011254800_bvaf141-B12","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S2468-1253(21)00191-6","article-title":"Barriers to the management of alcohol use disorder and alcohol-associated liver disease: strategies to implement integrated care models","volume":"7","author":"Dimartini","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"2025100909011254800_bvaf141-B13","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0893-133X(01)00367-0","article-title":"From first drug use to drug dependence developmental periods of risk for dependence upon marijuana, cocaine, and alcohol","volume":"26","author":"Wagner","year":"2002","journal-title":"Neuropsychopharmacology"},{"key":"2025100909011254800_bvaf141-B14","author":"World Health Organization"},{"issue":"6","key":"2025100909011254800_bvaf141-B15","doi-asserted-by":"crossref","first-page":"851","DOI":"10.3945\/an.114.007120","article-title":"Variety, palatability, and obesity","volume":"5","author":"Johnson","year":"2014","journal-title":"Advances in Nutrition"},{"issue":"7","key":"2025100909011254800_bvaf141-B16","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1038\/npp.2016.269","article-title":"Pathological overeating: emerging evidence for a compulsivity construct","volume":"42","author":"Moore","year":"2017","journal-title":"Neuropsychopharmacology"},{"issue":"13","key":"2025100909011254800_bvaf141-B17","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1038\/s41386-018-0203-9","article-title":"Food addiction: a valid concept?","volume":"43","author":"Fletcher","year":"2018","journal-title":"Neuropsychopharmacology"},{"issue":"9","key":"2025100909011254800_bvaf141-B18","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1002\/oby.23834","article-title":"How images of food become cravingly salient in obesity","volume":"31","author":"Devoto","year":"2023","journal-title":"Obesity"},{"issue":"3","key":"2025100909011254800_bvaf141-B19","doi-asserted-by":"crossref","first-page":"811","DOI":"10.2741\/4618","article-title":"Food addiction A common neurobiological mechanism with drug abuse","volume":"23","author":"Wang","year":"2018","journal-title":"Front Biosci"},{"issue":"4","key":"2025100909011254800_bvaf141-B20","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1056\/NEJMra1511480","article-title":"Neurobiologic advances from the brain disease model of addiction","volume":"374","author":"Volkow","year":"2016","journal-title":"N Engl J Med"},{"issue":"9253","key":"2025100909011254800_bvaf141-B21","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/S0140-6736(00)03643-6","article-title":"Brain dopamine and obesity","volume":"357","author":"Wang","year":"2001","journal-title":"The Lancet"},{"issue":"2","key":"2025100909011254800_bvaf141-B22","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1080\/15622975.2016.1249952","article-title":"Hepatic, lipid and genetic factors associated with obesity: crosstalk with alcohol dependence?","volume":"18","author":"Goodyear","year":"2017","journal-title":"World J Biol Psychiatry"},{"issue":"6","key":"2025100909011254800_bvaf141-B23","doi-asserted-by":"crossref","first-page":"e195844","DOI":"10.1001\/jamanetworkopen.2019.5844","article-title":"Association of high-intensity binge drinking with lipid and liver function enzyme levels","volume":"2","author":"Rosoff","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"11","key":"2025100909011254800_bvaf141-B24","doi-asserted-by":"crossref","first-page":"e2447644","DOI":"10.1001\/jamanetworkopen.2024.47644","article-title":"Alcohol use and antiobesity medication treatment","volume":"7","author":"Miller-Matero","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"2","key":"2025100909011254800_bvaf141-B25","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/j.1530-0277.2010.01334.x","article-title":"Role of feeding-related pathways in alcohol dependence: a focus on sweet preference, NPY, and ghrelin","volume":"35","author":"Leggio","year":"2011","journal-title":"Alcohol Clin Exp Res"},{"key":"2025100909011254800_bvaf141-B26","doi-asserted-by":"crossref","DOI":"10.1101\/2024.05.03.24306773","volume-title":"Alcohol use Disorder and Body Mass index Show Genetic Pleiotropy and Shared Neural Associations","author":"Malone","year":"2024"},{"key":"2025100909011254800_bvaf141-B27","volume-title":"Alcohol use Disorder","author":"Nehring","year":"2024"},{"issue":"2","key":"2025100909011254800_bvaf141-B28","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1080\/20009666.2020.1742495","article-title":"Substance use disorders: diagnosis and management for hospitalists","volume":"10","author":"Pasha","year":"2020","journal-title":"J Community Hosp Intern Med Perspect"},{"issue":"10031","key":"2025100909011254800_bvaf141-B29","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1016\/S0140-6736(16)00271-3","article-title":"Management of obesity","volume":"387","author":"Bray","year":"2016","journal-title":"The Lancet"},{"issue":"4","key":"2025100909011254800_bvaf141-B30","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/obr.12266","article-title":"Impact of weight bias and stigma on quality of care and outcomes for patients with obesity","volume":"16","author":"Phelan","year":"2015","journal-title":"Obes Rev"},{"issue":"14","key":"2025100909011254800_bvaf141-B31","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJMp1917360","article-title":"Stigma and the toll of addiction","volume":"382","author":"Volkow","year":"2020","journal-title":"N Engl J Med"},{"issue":"13","key":"2025100909011254800_bvaf141-B32","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1038\/s41386-021-01069-4","article-title":"Choosing appropriate language to reduce the stigma around mental illness and substance use disorders","volume":"46","author":"Volkow","year":"2021","journal-title":"Neuropsychopharmacology"},{"issue":"9","key":"2025100909011254800_bvaf141-B33","doi-asserted-by":"crossref","first-page":"eaax4043","DOI":"10.1126\/sciadv.aax4043","article-title":"Advances in the science and treatment of alcohol use disorder","volume":"5","author":"Witkiewitz","year":"2019","journal-title":"Sci Adv"},{"issue":"4","key":"2025100909011254800_bvaf141-B34","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1080\/14728214.2017.1395855","article-title":"Medications for substance use disorders (SUD): emerging approaches","volume":"22","author":"Butelman","year":"2017","journal-title":"Expert Opin Emerg Drugs"},{"issue":"17","key":"2025100909011254800_bvaf141-B35","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1001\/jama.2023.19761","article-title":"Pharmacotherapy for alcohol use disorder","volume":"330","author":"McPheeters","year":"2023","journal-title":"JAMA"},{"key":"2025100909011254800_bvaf141-B36","first-page":"261","volume-title":"Approved, Promising, and Experimental Medications for Treatment of Alcohol Use Disorder","author":"L\u00e9k\u00f3","year":"2023"},{"issue":"5","key":"2025100909011254800_bvaf141-B37","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1111\/add.16421","article-title":"Efficacy and safety of alcohol reduction pharmacotherapy according to treatment duration in patients with alcohol dependence or alcohol use disorder: a systematic review and network meta-analysis","volume":"119","author":"Kotake","year":"2024","journal-title":"Addiction"},{"issue":"11","key":"2025100909011254800_bvaf141-B38","doi-asserted-by":"crossref","first-page":"e172889","DOI":"10.1172\/JCI172889","article-title":"Novel medications for problematic alcohol use","volume":"134","author":"Heilig","year":"2024","journal-title":"J Clin Invest"},{"issue":"1","key":"2025100909011254800_bvaf141-B39","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/s41380-020-0661-4","article-title":"The changing opioid crisis: development, challenges and opportunities","volume":"26","author":"Volkow","year":"2021","journal-title":"Mol Psychiatry"},{"issue":"1","key":"2025100909011254800_bvaf141-B40","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.mcna.2021.08.011","article-title":"Tobacco use disorder","volume":"106","author":"Leone","year":"2022","journal-title":"Med Clin North Am"},{"issue":"6","key":"2025100909011254800_bvaf141-B41","doi-asserted-by":"crossref","first-page":"e208279","DOI":"10.1001\/jamanetworkopen.2020.8279","article-title":"Combined pharmacotherapy and cognitive behavioral therapy for adults with alcohol or substance use disorders","volume":"3","author":"Ray","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"3","key":"2025100909011254800_bvaf141-B42","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1007\/s13668-024-00551-x","article-title":"Weight loss programs: why do they fail? A multidimensional approach for obesity management","volume":"13","author":"Khattab","year":"2024","journal-title":"Curr Nutr Rep"},{"key":"2025100909011254800_bvaf141-B43","author":"Tchang"},{"issue":"8","key":"2025100909011254800_bvaf141-B44","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1016\/j.soard.2017.03.021","article-title":"Alcohol and other substance use after bariatric surgery: prospective evidence from a U.S. multicenter cohort study","volume":"13","author":"King","year":"2017","journal-title":"Surg Obes Relat Dis"},{"issue":"7","key":"2025100909011254800_bvaf141-B45","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1038\/npp.2016.246","article-title":"Endogenous glucagon-like peptide-1 receptor signaling in the nucleus tractus Solitarius is required for food intake control","volume":"42","author":"Alhadeff","year":"2017","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"2025100909011254800_bvaf141-B46","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s13300-011-0002-3","article-title":"Incretin-based therapy: a powerful and promising weapon in the treatment of type 2 diabetes mellitus","volume":"2","author":"Koliaki","year":"2011","journal-title":"Diabetes Ther"},{"issue":"8","key":"2025100909011254800_bvaf141-B47","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/BF00401145","article-title":"Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients","volume":"36","author":"Nauck","year":"1993","journal-title":"Diabetologia"},{"issue":"1","key":"2025100909011254800_bvaf141-B48","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.metabol.2013.09.010","article-title":"Anti-diabetic actions of glucagon-like peptide-1 on pancreatic beta-cells","volume":"63","author":"Lee","year":"2014","journal-title":"Metabolism"},{"key":"2025100909011254800_bvaf141-B49","doi-asserted-by":"crossref","first-page":"e614884","DOI":"10.3389\/fnbeh.2020.614884","article-title":"Can GLP-1 be a target for reward system related disorders? A qualitative synthesis and systematic review analysis of studies on palatable food, drugs of abuse, and alcohol","volume":"14","author":"Eren-Yazicioglu","year":"2021","journal-title":"Front Behav Neurosci"},{"issue":"5","key":"2025100909011254800_bvaf141-B50","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1038\/mp.2017.187","article-title":"Lateral hypothalamic GLP-1 receptors are critical for the control of food reinforcement, ingestive behavior and body weight","volume":"23","author":"L\u00f3pez-Ferreras","year":"2018","journal-title":"Mol Psychiatry"},{"key":"2025100909011254800_bvaf141-B51","doi-asserted-by":"crossref","first-page":"101352","DOI":"10.1016\/j.molmet.2021.101352","article-title":"Time and metabolic state-dependent effects of GLP-1R agonists on NPY\/AgRP and POMC neuronal activity in vivo","volume":"54","author":"Dong","year":"2021","journal-title":"Mol Metab"},{"issue":"6741","key":"2025100909011254800_bvaf141-B52","doi-asserted-by":"crossref","first-page":"eadt0773","DOI":"10.1126\/science.adt0773","article-title":"Hedonic eating is controlled by dopamine neurons that oppose GLP-1R satiety","volume":"387","author":"Zhu","year":"2025","journal-title":"Science"},{"key":"2025100909011254800_bvaf141-B53","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.physbeh.2019.03.026","article-title":"Central GLP-1 receptors: novel molecular targets for cocaine use disorder","volume":"206","author":"Hernandez","year":"2019","journal-title":"Physiol Behav"},{"issue":"11","key":"2025100909011254800_bvaf141-B54","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/nrn3105","article-title":"Common cellular and molecular mechanisms in obesity and drug addiction","volume":"12","author":"Kenny","year":"2011","journal-title":"Nat Rev Neurosci"},{"key":"2025100909011254800_bvaf141-B55","doi-asserted-by":"crossref","first-page":"107312","DOI":"10.1016\/j.phrs.2024.107312","article-title":"IUPHAR review\u2014glucagon-like peptide-1 (GLP-1) and substance use disorders: an emerging pharmacotherapeutic target","volume":"207","author":"Bruns Vi","year":"2024","journal-title":"Pharmacol Res"},{"issue":"8","key":"2025100909011254800_bvaf141-B56","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/j.psyneuen.2012.11.009","article-title":"The glucagon-like peptide 1 analogue exendin-4 attenuates alcohol mediated behaviors in rodents","volume":"38","author":"Egecioglu","year":"2013","journal-title":"Psychoneuroendocrinology"},{"issue":"2","key":"2025100909011254800_bvaf141-B57","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/adb.12295","article-title":"The glucagon-like peptide 1 receptor agonist liraglutide attenuates the reinforcing properties of alcohol in rodents","volume":"21","author":"Vall\u00f6f","year":"2016","journal-title":"Addict Biol"},{"key":"2025100909011254800_bvaf141-B58","doi-asserted-by":"crossref","first-page":"e599646","DOI":"10.3389\/fnins.2020.599646","article-title":"Long-acting glucagon-like peptide-1 receptor agonists suppress voluntary alcohol intake in male wistar rats","volume":"14","author":"Marty","year":"2020","journal-title":"Front Neurosci"},{"key":"2025100909011254800_bvaf141-B59","doi-asserted-by":"crossref","first-page":"104642","DOI":"10.1016\/j.ebiom.2023.104642","article-title":"Semaglutide reduces alcohol intake and relapse-like drinking in male and female rats","volume":"93","author":"Aran\u00e4s","year":"2023","journal-title":"eBioMedicine"},{"issue":"12","key":"2025100909011254800_bvaf141-B60","doi-asserted-by":"crossref","first-page":"e170671","DOI":"10.1172\/jci.insight.170671","article-title":"The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission","volume":"8","author":"Chuong","year":"2023","journal-title":"JCI Insight"},{"issue":"1","key":"2025100909011254800_bvaf141-B61","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s00213-024-06637-2","article-title":"Effect of the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide on alcohol consumption in alcohol-preferring male vervet monkeys","volume":"242","author":"Fink-Jensen","year":"2024","journal-title":"Psychopharmacology (Berl)"},{"issue":"2","key":"2025100909011254800_bvaf141-B62","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s00213-018-5089-z","article-title":"Effects of glucagon-like peptide 1 analogs on alcohol intake in alcohol-preferring vervet monkeys","volume":"236","author":"Thomsen","year":"2019","journal-title":"Psychopharmacology (Berl)"},{"issue":"6","key":"2025100909011254800_bvaf141-B63","doi-asserted-by":"crossref","first-page":"617","DOI":"10.3390\/brainsci14060617","article-title":"Exploring the potential impact of GLP-1 receptor agonists on substance use, compulsive behavior, and libido: insights from social Media using a mixed-methods approach","volume":"14","author":"Arillotta","year":"2024","journal-title":"Brain Sci"},{"issue":"1","key":"2025100909011254800_bvaf141-B64","first-page":"5","article-title":"Social media as pharmacovigilance: the potential for patient reports to inform clinical research on glucagon-like peptide 1 (GLP-1) receptor agonists for substance use disorders","volume":"85","author":"Bremmer","year":"2023","journal-title":"J Stud Alcohol Drugs"},{"issue":"1","key":"2025100909011254800_bvaf141-B65","doi-asserted-by":"crossref","first-page":"20998","DOI":"10.1038\/s41598-023-48267-2","article-title":"Semaglutide and tirzepatide reduce alcohol consumption in individuals with obesity","volume":"13","author":"Quddos","year":"2023","journal-title":"Sci Rep"},{"issue":"5","key":"2025100909011254800_bvaf141-B66","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/bcpt.13776","article-title":"Use of GLP-1 receptor agonists and subsequent risk of alcohol-related events. A nationwide register-based cohort and self-controlled case series study","volume":"131","author":"Wium-Andersen","year":"2022","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"1","key":"2025100909011254800_bvaf141-B67","doi-asserted-by":"crossref","first-page":"4548","DOI":"10.1038\/s41467-024-48780-6","article-title":"Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population","volume":"15","author":"Wang","year":"2024","journal-title":"Nat Commun"},{"issue":"1","key":"2025100909011254800_bvaf141-B68","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1001\/jamapsychiatry.2024.3599","article-title":"Repurposing semaglutide and liraglutide for alcohol use disorder","volume":"82","author":"L\u00e4hteenvuo","year":"2025","journal-title":"JAMA Psychiatry"},{"issue":"2","key":"2025100909011254800_bvaf141-B69","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/add.16679","article-title":"The association between glucose-dependent insulinotropic polypeptide and\/or glucagon-like peptide-1 receptor agonist prescriptions and substance-related outcomes in patients with opioid and alcohol use disorders: a real-world data analysis","volume":"120","author":"Qeadan","year":"2025","journal-title":"Addiction"},{"issue":"9","key":"2025100909011254800_bvaf141-B70","doi-asserted-by":"crossref","first-page":"e188314","DOI":"10.1172\/JCI188314","article-title":"Glucagon-like peptide-1 receptor agonists but not dipeptidyl peptidase-4 inhibitors reduce alcohol intake","volume":"135","author":"Farokhnia","year":"2025","journal-title":"J Clin Invest"},{"issue":"19","key":"2025100909011254800_bvaf141-B71","doi-asserted-by":"crossref","first-page":"e159863","DOI":"10.1172\/jci.insight.159863","article-title":"Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial","volume":"7","author":"Klausen","year":"2022","journal-title":"JCI Insight"},{"issue":"4):","key":"2025100909011254800_bvaf141-B72","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1001\/jamapsychiatry.2024.4789","article-title":"Once-weekly semaglutide in adults with alcohol use disorder","volume":"82","author":"Hendershot","year":"2025","journal-title":"JAMA Psychiatry"},{"issue":"2","key":"2025100909011254800_bvaf141-B73","doi-asserted-by":"crossref","first-page":"e13117","DOI":"10.1111\/adb.13117","article-title":"Glucagon-like peptide-1 receptor agonist, liraglutide, reduces heroin self-administration and drug-induced reinstatement of heroin-seeking behaviour in rats","volume":"27","author":"Douton","year":"2022","journal-title":"Addict Biol"},{"issue":"5","key":"2025100909011254800_bvaf141-B74","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1097\/FBP.0000000000000685","article-title":"Acute glucagon-like peptide-1 receptor agonist liraglutide prevents cue-, stress-, and drug-induced heroin-seeking in rats","volume":"33","author":"Douton","year":"2022","journal-title":"Behav Pharmacol"},{"issue":"3","key":"2025100909011254800_bvaf141-B75","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/s41386-019-0531-4","article-title":"Activation of GLP-1 receptors attenuates oxycodone taking and seeking without compromising the antinociceptive effects of oxycodone in rats","volume":"45","author":"Zhang","year":"2020","journal-title":"Neuropsychopharmacology"},{"key":"2025100909011254800_bvaf141-B76","doi-asserted-by":"crossref","first-page":"108599","DOI":"10.1016\/j.neuropharm.2021.108599","article-title":"A novel dual agonist of glucagon-like peptide-1 receptors and neuropeptide Y2 receptors attenuates fentanyl taking and seeking in male rats","volume":"192","author":"Zhang","year":"2021","journal-title":"Neuropharmacology"},{"issue":"2","key":"2025100909011254800_bvaf141-B77","doi-asserted-by":"crossref","first-page":"ENEURO.0443-18","DOI":"10.1523\/ENEURO.0443-18.2019","article-title":"Glucagon-like peptide-1 receptor agonist treatment does not reduce abuse-related effects of opioid drugs","volume":"6","author":"Bornebusch","year":"2019","journal-title":"eneuro"},{"issue":"9","key":"2025100909011254800_bvaf141-B78","doi-asserted-by":"crossref","first-page":"e2435247","DOI":"10.1001\/jamanetworkopen.2024.35247","article-title":"Semaglutide and opioid overdose risk in patients with type 2 diabetes and opioid use disorder","volume":"7","author":"Wang","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"6","key":"2025100909011254800_bvaf141-B79","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1007\/s00213-023-06376-w","article-title":"Liraglutide attenuates nicotine self-administration as well as nicotine seeking and hyperphagia during withdrawal in male and female rats","volume":"240","author":"Herman","year":"2023","journal-title":"Psychopharmacology (Berl)"},{"issue":"5","key":"2025100909011254800_bvaf141-B80","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/nn.4540","article-title":"GLP-1 acts on habenular avoidance circuits to control nicotine intake","volume":"20","author":"Tuesta","year":"2017","journal-title":"Nat Neurosci"},{"issue":"8","key":"2025100909011254800_bvaf141-B81","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.7326\/M23-2718","article-title":"Association of semaglutide with tobacco use disorder in patients with type 2 diabetes","volume":"177","author":"Wang","year":"2024","journal-title":"Ann Intern Med"},{"issue":"10","key":"2025100909011254800_bvaf141-B82","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1093\/ntr\/ntab066","article-title":"Exenatide adjunct to nicotine patch facilitates smoking cessation and may reduce post-cessation weight gain: a pilot randomized controlled trial","volume":"23","author":"Yammine","year":"2021","journal-title":"Nicotine Tob Res"},{"issue":"7):","key":"2025100909011254800_bvaf141-B83","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1093\/ntr\/ntaf005","article-title":"Exploring predictors of treatment response to GLP-1 receptor agonists for smoking cessation","volume":"27","author":"Yammine","year":"2025","journal-title":"Nicotine Tob Res"},{"key":"2025100909011254800_bvaf141-B84","doi-asserted-by":"crossref","first-page":"101865","DOI":"10.1016\/j.eclinm.2023.101865","article-title":"Effect of dulaglutide in promoting abstinence during smoking cessation: a single-centre, randomized, double-blind, placebo-controlled, parallel group trial","volume":"57","author":"Lengsfeld","year":"2023","journal-title":"eClinicalMedicine"},{"issue":"22","key":"2025100909011254800_bvaf141-B85","doi-asserted-by":"crossref","first-page":"e170419","DOI":"10.1172\/jci.insight.170419","article-title":"Effects of dulaglutide on alcohol consumption during smoking cessation","volume":"8","author":"Probst","year":"2023","journal-title":"JCI Insight"},{"key":"2025100909011254800_bvaf141-B86","doi-asserted-by":"crossref","first-page":"102429","DOI":"10.1016\/j.eclinm.2024.102429","article-title":"Effect of dulaglutide in promoting abstinence during smoking cessation: 12-month follow-up of a single-centre, randomised, double-blind, placebo-controlled, parallel group trial","volume":"68","author":"L\u00fcthi","year":"2024","journal-title":"eClinicalMedicine"},{"issue":"8","key":"2025100909011254800_bvaf141-B87","doi-asserted-by":"crossref","first-page":"4394","DOI":"10.1038\/s41380-020-00957-3","article-title":"GLP-1 receptor signaling in the laterodorsal tegmental nucleus attenuates cocaine seeking by activating GABAergic circuits that project to the VTA","volume":"26","author":"Hernandez","year":"2021","journal-title":"Mol Psychiatry"},{"key":"2025100909011254800_bvaf141-B88","doi-asserted-by":"crossref","DOI":"10.1101\/2024.06.20.599574","volume-title":"An Endogenous GLP-1 Circuit Engages VTA GABA Neurons to Regulate Mesolimbic Dopamine Neurons and Attenuate Cocaine Seeking","author":"Merkel","year":"2024"},{"issue":"8","key":"2025100909011254800_bvaf141-B89","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1038\/npp.2015.47","article-title":"Septal glucagon-like peptide 1 receptor expression determines suppression of cocaine-induced behavior","volume":"40","author":"Harasta","year":"2015","journal-title":"Neuropsychopharmacology"},{"issue":"5","key":"2025100909011254800_bvaf141-B90","doi-asserted-by":"crossref","first-page":"e809","DOI":"10.1038\/tp.2016.86","article-title":"Glucagon-like peptide 1 receptor activation regulates cocaine actions and dopamine homeostasis in the lateral septum by decreasing arachidonic acid levels","volume":"6","author":"Reddy","year":"2016","journal-title":"Transl Psychiatry"},{"issue":"4","key":"2025100909011254800_bvaf141-B91","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.physbeh.2012.03.014","article-title":"Exendin-4 decreases amphetamine-induced locomotor activity","volume":"106","author":"Erreger","year":"2012","journal-title":"Physiol Behav"},{"key":"2025100909011254800_bvaf141-B92","doi-asserted-by":"crossref","first-page":"769664","DOI":"10.3389\/fnbeh.2021.769664","article-title":"Effects of glucagon-like peptide-1 receptor agonist exendin-4 on the reinstatement of cocaine-mediated conditioned place preference in mice","volume":"15","author":"Zhu","year":"2022","journal-title":"Front Behav Neurosci"},{"key":"2025100909011254800_bvaf141-B93","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.physbeh.2015.06.013","article-title":"The glucagon-like peptide 1 (GLP-1) receptor agonist exendin-4 reduces cocaine self-administration in mice","volume":"149","author":"S\u00f8rensen","year":"2015","journal-title":"Physiol Behav"},{"key":"2025100909011254800_bvaf141-B94","doi-asserted-by":"crossref","first-page":"109872","DOI":"10.1016\/j.pnpbp.2020.109872","article-title":"The GLP-1 receptor agonist liraglutide reverses mania-like alterations and memory deficits induced by D-amphetamine and augments lithium effects in mice: relevance for bipolar disorder","volume":"99","author":"Chaves Filho","year":"2020","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"2025100909011254800_bvaf141-B95","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.drugalcdep.2017.07.033","article-title":"Acute effects of intravenous cocaine administration on serum concentrations of ghrelin, amylin, glucagon-like peptide-1, insulin, leptin and peptide YY and relationships with cardiorespiratory and subjective responses","volume":"180","author":"Bouhlal","year":"2017","journal-title":"Drug Alcohol Depend"},{"key":"2025100909011254800_bvaf141-B96","doi-asserted-by":"crossref","first-page":"108614","DOI":"10.1016\/j.drugalcdep.2021.108614","article-title":"Testing the effects of the GLP-1 receptor agonist exenatide on cocaine self-administration and subjective responses in humans with cocaine use disorder","volume":"221","author":"Angarita","year":"2021","journal-title":"Drug Alcohol Depend"},{"issue":"6","key":"2025100909011254800_bvaf141-B97","doi-asserted-by":"crossref","first-page":"855","DOI":"10.3390\/biom10060855","article-title":"Targeting the endocannabinoid CB1 receptor to treat body weight disorders: a preclinical and clinical review of the therapeutic potential of past and present CB1 drugs","volume":"10","author":"Murphy","year":"2020","journal-title":"Biomolecules"},{"key":"2025100909011254800_bvaf141-B98","doi-asserted-by":"crossref","first-page":"107477","DOI":"10.1016\/j.pharmthera.2020.107477","article-title":"The therapeutic potential of second and third generation CB1R antagonists","volume":"208","author":"Cinar","year":"2020","journal-title":"Pharmacol Ther"},{"issue":"1","key":"2025100909011254800_bvaf141-B99","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41398-020-0756-3","article-title":"Effects of oral, smoked, and vaporized cannabis on endocrine pathways related to appetite and metabolism: a randomized, double-blind, placebo-controlled, human laboratory study","volume":"10","author":"Farokhnia","year":"2020","journal-title":"Transl Psychiatry"},{"issue":"8","key":"2025100909011254800_bvaf141-B100","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1038\/s41380-024-02498-5","article-title":"Association of semaglutide with reduced incidence and relapse of cannabis use disorder in real-world populations: a retrospective cohort study","volume":"29","author":"Wang","year":"2024","journal-title":"Mol Psychiatry"},{"issue":"12","key":"2025100909011254800_bvaf141-B101","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1038\/s41591-023-02634-8","article-title":"GLP-1 receptor agonists are promising but unproven treatments for alcohol and substance use disorders","volume":"29","author":"Leggio","year":"2023","journal-title":"Nat Med"},{"issue":"2","key":"2025100909011254800_bvaf141-B102","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/add.16626","article-title":"GLP-1R agonist medications for addiction treatment","volume":"120","author":"Volkow","year":"2025","journal-title":"Addiction"},{"key":"2025100909011254800_bvaf141-B103","doi-asserted-by":"crossref","first-page":"100127","DOI":"10.1016\/j.obpill.2024.100127","article-title":"Glucagon-like receptor-1 agonists for obesity: weight loss outcomes, tolerability, side effects, and risks","volume":"12","author":"Ghusn","year":"2024","journal-title":"Obes Pillars"},{"issue":"16","key":"2025100909011254800_bvaf141-B104","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1161\/CIRCULATIONAHA.124.067676","article-title":"Muscle mass and glucagon-like peptide-1 receptor agonists: adaptive or maladaptive response to weight loss?","volume":"150","author":"Linge","year":"2024","journal-title":"Circulation"},{"key":"2025100909011254800_bvaf141-B105","doi-asserted-by":"crossref","first-page":"8056440","DOI":"10.1155\/2024\/8056440","article-title":"A comprehensive review on weight gain following discontinuation of glucagon-like peptide-1 receptor agonists for obesity","volume":"2024","author":"Abdullah Bin Ahmed","year":"2024","journal-title":"J Obes"},{"issue":"6","key":"2025100909011254800_bvaf141-B106","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1002\/oby.24027","article-title":"Physiology of the weight-loss plateau in response to diet restriction, GLP-1 receptor agonism, and bariatric surgery","volume":"32","author":"Hall","year":"2024","journal-title":"Obesity"},{"key":"2025100909011254800_bvaf141-B107","author":"European Medicines Agency"},{"key":"2025100909011254800_bvaf141-B108","author":"US Food and Drug Administration"},{"issue":"1","key":"2025100909011254800_bvaf141-B109","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1080\/14740338.2023.2295397","article-title":"The association between glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: reports to the food and drug administration adverse event reporting system (FAERS)","volume":"23","author":"McIntyre","year":"2024","journal-title":"Expert Opin Drug Saf"}],"container-title":["Journal of the Endocrine Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jes\/article-pdf\/9\/11\/bvaf141\/64550308\/bvaf141.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jes\/article-pdf\/9\/11\/bvaf141\/64550308\/bvaf141.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T13:01:30Z","timestamp":1760014890000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jes\/article\/doi\/10.1210\/jendso\/bvaf141\/8277723"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,8]]},"references-count":109,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,10,8]]}},"URL":"https:\/\/doi.org\/10.1210\/jendso\/bvaf141","relation":{},"ISSN":["2472-1972"],"issn-type":[{"value":"2472-1972","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,11]]},"published":{"date-parts":[[2025,10,8]]},"article-number":"bvaf141"}}